argenx NV ADR (ARGX) - Total Liabilities
Based on the latest financial reports, argenx NV ADR (ARGX) has total liabilities worth $1.36 Billion USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore argenx NV ADR equity growth rate to track the company's year-over-year net asset growth rate.
argenx NV ADR - Total Liabilities Trend (2010–2025)
This chart illustrates how argenx NV ADR's total liabilities have evolved over time, based on quarterly financial data. See free cash flow generation of argenx NV ADR to measure how efficiently the company converts operating cash flow to free cash.
argenx NV ADR Competitors by Total Liabilities
The table below lists competitors of argenx NV ADR ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Swedbank AB (publ)
ST:SWED-A
|
Sweden | Skr2.99 Trillion |
|
Hess Corporation
NYSE:HES
|
USA | $14.75 Billion |
|
Constellation Software Inc.
TO:CSU
|
Canada | CA$11.22 Billion |
|
ING Groep N.V
MX:INGN
|
Mexico | MX$1.00 Trillion |
|
Suzhou Dongshan Precision Manufacturing Co Ltd
SHE:002384
|
China | CN¥40.15 Billion |
|
Ambev SA ADR
NYSE:ABEV
|
USA | $51.94 Billion |
|
Garmin Ltd
NYSE:GRMN
|
USA | $1.68 Billion |
|
HOLCIM NEW(U.ADR)1/5/SF2
F:HLB
|
Germany | €17.52 Billion |
Liability Composition Analysis (2010–2025)
This chart breaks down argenx NV ADR's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see argenx NV ADR stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.23 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.19 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.16 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how argenx NV ADR's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for argenx NV ADR (2010–2025)
The table below shows the annual total liabilities of argenx NV ADR from 2010 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $1.36 Billion | +93.06% |
| 2024-12-31 | $704.24 Million | +58.27% |
| 2023-12-31 | $444.95 Million | +38.80% |
| 2022-12-31 | $320.56 Million | +1.43% |
| 2021-12-31 | $316.05 Million | -47.79% |
| 2020-12-31 | $605.36 Million | +40.84% |
| 2019-12-31 | $429.81 Million | +837.86% |
| 2018-12-31 | $45.83 Million | +47.05% |
| 2017-12-31 | $31.16 Million | -30.11% |
| 2016-12-31 | $44.59 Million | +372.68% |
| 2015-12-31 | $9.43 Million | +11.93% |
| 2014-12-31 | $8.43 Million | +84.50% |
| 2013-12-31 | $4.57 Million | -27.24% |
| 2012-12-31 | $6.28 Million | +55.28% |
| 2011-12-31 | $4.04 Million | +99.26% |
| 2010-12-31 | $2.03 Million | -- |
About argenx NV ADR
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgarti… Read more